Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

NCT02325557 is registered in ClinicalTrials.gov with Advaxis, Inc. as lead sponsor.

NCT NCT02325557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02325557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Advaxis, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 4, 2015
Completion date
January 22, 2020
Enrollment
50 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, prostate cancer